| References: |
BMS309403 is orally active, reducing atherosclerosis in mice lacking apoplipoprotein E.It also protects against the development of insulin resistance associated with genetic or diet-induced obesity in mice.FABP4 dose-dependently suppresses the release of MCP-1 from macrophages. For the detailed information of BMS-309403, the solubility of BMS-309403 in water, the solubility of BMS-309403 in DMSO, the solubility of BMS-309403 in PBS buffer, the animal experiment (test) of BMS-309403, the cell expriment (test) of BMS-309403, the in vivo, in vitro and clinical trial test of BMS-309403, the EC50, IC50,and affinity,of BMS-309403, For the detailed information of BMS-309403, the solubility of BMS-309403 in water, the solubility of BMS-309403 in DMSO, the solubility of BMS-309403 in PBS buffer, the animal experiment (test) of BMS-309403, the cell expriment (test) of BMS-309403, the in vivo, in vitro and clinical trial test of BMS-309403, the EC50, IC50,and affinity,of BMS-309403, Please contact DC Chemicals. |
